bellavista 1000 Ventilator (Vyaire) – Patient Safety Risks (2023)
Ventilator touchscreen issues may interrupt critical patient ventilation.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
bellavista 1000 Ventilator, Catalogue Number 301.100.030; Continuous Use Ventilator
Brand
Vyaire Medical
Lot Codes / Batch Numbers
UDI/DI: 10190752197664 and 07640149381115, ALL serial numbers with Software Version 6.1.0.2 and 6.1.1
Products Sold
UDI/DI: 10190752197664 and 07640149381115, ALL serial numbers with Software Version 6.1.0.2 and 6.1.1
Vyaire Medical is recalling bellavista 1000 Ventilator, Catalogue Number 301.100.030; Continuous Use Ventilator due to Vyaire Medical identified two patient safety risks during the use of the bellavista 1000 and bellavista 1000e: 1. Under certain conditions of use, the. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Vyaire Medical identified two patient safety risks during the use of the bellavista 1000 and bellavista 1000e: 1. Under certain conditions of use, the touchscreen may become unresponsive and the device application stops responding (APP Hang). When this occurs, if the user continues to interact with the touchscreen, a message will appear that states DeviceSoftware.Application is not responding or a decommission screen will appear on the user interface. The ventilator will issue both an audible and visual alarm. Ventilation continues without interruption with the settings applied prior to the APP Hang error. 2. The potential for a use error has been identified if the operator applies the proposed settings without confirming the settings are suitable for the patient.
Recommended Action
Per FDA guidance
The firm notified its consignees by email on 04/27/2023. The notice explained the issue, the risk to health and requested the following: ACTIONS TO BE TAKEN BY CONSUMERS/END USERS 1. Confirm receipt and thoroughly review the contents of the Customer Notification package. 2. If affected devices are transferred to another location or organization, forward the complete Customer Notification package to the respective users. 3. To reduce the change that the AppHang error will occur, Vyaire recommends that when the )2 suction maneuver is active, the end user should not attempt to activate any controls or screens until: The O2 suction maneuver has timed or The O2 suction maneuver has been aborted by selecting the O2 suction button again to turn it off. Vyaire further recommends the following: User re-configures the screen to remove the circuit monitoring tile, if applicable. User does not connect anything to either of the two USB ports on the left side of the ventilator during patient ventilation. For more detailed instructions, please refer to Appendix A. Following these steps will help to reduce the likelihood of the AppHang occurring. 4. When transitioning between ventilation modes, always check and confirm the proposed settings. The proposed settings are based on the current level of support provided in the active mode at the time of the mode change. Special attention should be given when transitioning back from a spontaneous breathing mode such as Pressure Support Ventilation (PSV).
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026